GK |
body weight |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
367.0 |
g |
7.0 |
17.15 |
body weighing method |
0.0 |
0 |
|
|
103493 |
2827 |
WKY/NCrl |
water intake drink rate to body weight ratio |
salidroside (40 mg/kg) (between 1 and 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
drinking behavior trait |
male |
140 days-175 days |
6 |
50.0 |
ml/d/kg |
1.0 |
2.45 |
drink intake measuring method |
|
0 |
|
|
103499 |
2827 |
GK |
serum fructosamine level |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood fructosamine amount |
male |
175 days
| 5 |
199.0 |
umol/l |
12.0 |
29.39 |
serum fructosamine analysis |
0.0 |
0 |
|
|
103505 |
2827 |
WKY/NCrl |
blood glucose level |
salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood glucose amount |
male |
168 days
| 6 |
121.0 |
mg/dl |
2.0 |
4.9 |
oral glucose tolerance test |
0.0 |
0 |
|
|
103519 |
2827 |
WKY/NCrl |
systolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 6 |
123.0 |
mmHg |
2.0 |
4.9 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103535 |
2827 |
GK |
diastolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 5 |
99.0 |
mmHg |
3.0 |
6.71 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103545 |
2827 |
WKY/NCrl |
diastolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 6 |
87.0 |
mmHg |
2.0 |
4.9 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103551 |
2827 |
WKY/NCrl |
heart rate |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
heart pumping trait |
male |
168 days
| 6 |
284.0 |
beats/min |
4.0 |
9.8 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103559 |
2827 |
WKY/NCrl |
heart rate |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
heart pumping trait |
male |
168 days
| 6 |
334.0 |
beats/min |
3.0 |
7.35 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103567 |
2827 |
WKY/NCrl |
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-7.1 |
null |
0.04 |
0.11 |
wire myography |
|
0 |
|
|
103587 |
2827 |
GK |
logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-8.21 |
null |
0.06 |
0.16 |
wire myography |
0.0 |
0 |
|
|
103597 |
2827 |
WKY/NCrl |
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-7.72 |
null |
0.03 |
0.08 |
wire myography |
0.0 |
0 |
|
|
103603 |
2827 |
WKY/NCrl |
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
96.2 |
% |
1.31 |
3.47 |
wire myography |
0.0 |
0 |
|
|
103607 |
2827 |
WKY/NCrl |
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
90.13 |
% |
1.55 |
4.1 |
wire myography |
0.0 |
0 |
|
|
103615 |
2827 |
GK |
mesenteric artery phosphorylated eNOS level to total eNOS level ratio |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
artery molecular composition trait |
male |
175 days
| 7 |
0.94 |
null |
0.13 |
0.34 |
western blot assay |
0.0 |
0 |
|
|
103625 |
2827 |
GK |
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
98.78 |
% |
1.82 |
4.82 |
wire myography |
0.0 |
0 |
|
|
103617 |
2827 |
GK |
water intake drink rate to body weight ratio |
salidroside (40 mg/kg) (between 1 and 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
drinking behavior trait |
male |
140 days-175 days |
6 |
95.0 |
ml/d/kg |
11.0 |
26.94 |
drink intake measuring method |
|
0 |
|
|
103501 |
2827 |
WKY/NCrl |
serum fructosamine level |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood fructosamine amount |
male |
175 days
| 6 |
152.0 |
umol/l |
2.0 |
4.9 |
serum fructosamine analysis |
0.0 |
0 |
|
|
103503 |
2827 |
GK |
blood glucose level |
salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood glucose amount |
male |
168 days
| 6 |
141.0 |
mg/dl |
15.0 |
36.74 |
blood glucose test strip read by electrochemical glucometer |
0.0 |
0 |
|
|
103513 |
2827 |
GK |
systolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 5 |
139.0 |
mmHg |
3.0 |
6.71 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103529 |
2827 |
GK |
systolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 5 |
146.0 |
mmHg |
3.0 |
6.71 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103537 |
2827 |
GK |
heart rate |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
heart pumping trait |
male |
168 days
| 5 |
289.0 |
beats/min |
5.0 |
11.18 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103561 |
2827 |
GK |
heart rate |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
heart pumping trait |
male |
168 days
| 5 |
339.0 |
beats/min |
14.0 |
31.3 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103569 |
2827 |
WKY/NCrl |
number of spontaneous locomotor movements per unit time |
salidroside (40 mg/kg) (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
voluntary movement trait |
male |
168 days
| 6 |
1.0 |
/min |
0.1 |
0.24 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
number of spontaneous locomotor movements per unit time (CMO:0003644) |
103575 |
2827 |
GK |
number of spontaneous locomotor movements per unit time |
salidroside (40 mg/kg) (between 1 and 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
voluntary movement trait |
male |
168 days
| 5 |
1.0 |
/min |
0.1 |
0.22 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
number of spontaneous locomotor movements per unit time (CMO:0003644) |
103577 |
2827 |
GK |
number of spontaneous locomotor movements per unit time |
salidroside (40 mg/kg) (between 1 and 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
voluntary movement trait |
male |
168 days
| 5 |
3.5 |
/min |
0.4 |
0.89 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
number of spontaneous locomotor movements per unit time (CMO:0003644) |
103585 |
2827 |
WKY/NCrl |
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
90.64 |
% |
2.0 |
5.29 |
wire myography |
0.0 |
0 |
|
|
103591 |
2827 |
GK |
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-7.29 |
null |
0.02 |
0.06 |
wire myography |
0.0 |
0 |
|
|
103605 |
2827 |
GK |
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
97.14 |
% |
0.86 |
2.28 |
wire myography |
0.0 |
0 |
|
|
103601 |
2827 |
WKY/NCrl |
body weight |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
body mass |
male |
168 days
| 6 |
462.0 |
g |
6.0 |
14.7 |
body weighing method |
0.0 |
0 |
|
|
103491 |
2827 |
WKY/NCrl |
blood glucose level |
salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood glucose amount |
male |
168 days
| 6 |
103.0 |
mg/dl |
3.0 |
7.35 |
blood glucose test strip read by electrochemical glucometer |
0.0 |
0 |
|
|
103511 |
2827 |
WKY/NCrl |
systolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 6 |
117.0 |
mmHg |
2.0 |
4.9 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103527 |
2827 |
WKY/NCrl |
number of spontaneous locomotor movements per unit time |
salidroside (40 mg/kg) (between 1 and 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
voluntary movement trait |
male |
168 days
| 6 |
3.4 |
/min |
0.3 |
0.73 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
number of spontaneous locomotor movements per unit time (CMO:0003644) |
103583 |
2827 |
GK |
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
81.86 |
% |
1.91 |
5.04 |
wire myography |
0.0 |
0 |
|
|
103593 |
2827 |
GK |
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
98.82 |
% |
1.19 |
3.15 |
wire myography |
0.0 |
0 |
|
|
103609 |
2827 |
GK |
logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-8.35 |
null |
0.12 |
0.32 |
wire myography |
0.0 |
0 |
|
|
103613 |
2827 |
WKY/NCrl |
mesenteric artery phosphorylated eNOS level to total eNOS level ratio |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
artery molecular composition trait |
male |
175 days
| 7 |
0.88 |
null |
0.08 |
0.21 |
western blot assay |
0.0 |
0 |
|
|
103623 |
2827 |
WKY/NCrl |
logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-8.21 |
null |
0.07 |
0.19 |
wire myography |
0.0 |
0 |
|
|
103611 |
2827 |
WKY/NCrl |
logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-8.04 |
null |
0.04 |
0.12 |
wire myography |
0.0 |
0 |
|
|
103595 |
2827 |
WKY/NCrl |
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
98.36 |
% |
0.98 |
2.59 |
wire myography |
0.0 |
0 |
|
|
103599 |
2827 |
GK |
blood glucose level |
salidroside (40 mg/kg) (for 28 days) then fasting (for 16 hours) then glucose (2 g/kg) (for 2 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
blood glucose amount |
male |
168 days
| 6 |
297.0 |
mg/dl |
25.0 |
61.24 |
oral glucose tolerance test |
0.0 |
0 |
|
|
103521 |
2827 |
WKY/NCrl |
diastolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and light phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 6 |
83.0 |
mmHg |
2.0 |
4.9 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/day for 4 weeks |
daytime measurement |
103543 |
2827 |
GK |
diastolic blood pressure |
salidroside (40 mg/kg) (for 28 days) and dark phase of controlled light/dark cycle (for 12 hours) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
arterial blood pressure trait |
male |
168 days
| 5 |
105.0 |
mmHg |
3.0 |
6.71 |
intra-aortic abdominal radiotelemetry |
|
0 |
measured 12 hr/night for 4 weeks |
nighttime measurement |
103553 |
2827 |
GK |
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) |
salidroside (40 mg/kg) (for 28 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
vasodilation trait |
male |
168 days
| 7 |
-7.3 |
null |
0.05 |
0.13 |
wire myography |
|
0 |
|
|
103589 |
2827 |
GK |
aorta wall phosphorylated eNOS level to total eNOS level ratio |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
artery molecular composition trait |
male |
175 days
| 7 |
1.59 |
null |
0.36 |
0.95 |
western blot assay |
0.0 |
0 |
|
|
103621 |
2827 |
WKY/NCrl |
aorta wall phosphorylated eNOS level to total eNOS level ratio |
salidroside (40 mg/kg) (for 35 days) |
Alameddine A, et al., J Physiol Pharmacol. 2015 Apr;66(2):249-57. |
artery molecular composition trait |
male |
175 days
| 7 |
1.3 |
null |
0.27 |
0.71 |
western blot assay |
0.0 |
0 |
|
|
103619 |
2827 |